At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- ATTR-01 (drug)
- How long the study runs
- Study runs about 117 months (dates as stated)
- About the drug or intervention
- ATTR-01 — drug: Intravenous injection
- Patient visit burden
- Not specified by the sponsor
In plain English
This study is testing a treatment called ATTR-01 in adults with certain solid tumours that often have high levels of a protein called αvβ6 integrin on their surface. It is run by Accession Therapeutics Limited. The trial focuses on people whose cancer is a type that starts in lining tissues (epithelial).
Who can take part
- Adults aged 18 and over who consent to take part, with certain solid epithelial tumours known to often have high levels of a protein called αvβ6 integrin
- People who have already had standard treatment that did not work or caused bad side effects (not including treatment given before surgery)
- Have a tumour that was not treated with radiotherapy before, and that can safely have small samples (biopsies) taken before and after treatment
- Have cancer that can be measured using standard guidelines called RECIST Version 1.1
- Are well enough to care for themselves, based on a fitness score called ECOG of 0 or 1
- Are expected to live more than three months
- Are willing to follow good hygiene measures to avoid spreading a virus and to protect vulnerable people
- Have organs (such as the liver and kidneys) working well enough
- Are able to follow rules about waiting times after previous treatments and using contraception, as required for genetically modified organisms and cancer treatments
- Previous immunotherapy (immune checkpoint antibody treatment), alone or with other cancer drugs, is allowed
Who may not be able to
- People with a significant amount of fibrotic disease (scarring or thickening of tissue), including autoimmune diseases such as systemic lupus or rheumatoid arthritis, or lung fibrosis with no known cause or linked to their job
- People who have had bad side effects (toxicity) from immunotherapy drugs called PD-1 or PD-L1 treatments in the past
- People with other health conditions listed in the full trial rules
What taking part involves
- • Not stated — ask the trial team
Time commitment: Not stated — ask the trial team about the number of visits, how long the trial lasts, and what taking part involves.
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Testing a treatment
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 72
- Started
- 2025-03-21
- Last checked
- 2026-05
Plain English Summary
What is this study?
- • Testing a new treatment for solid tumor, adult
- • Phase1/Phase2 - 72 participants
- • ATTR-01 is the experimental drug being studied in the ATTEST clinical trial
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with solid tumor, adult
Where?
- • Glasgow - Beatson West of Scotland Cancer Centre
- • Cardiff - Velindre Cancer Centre
- • Leeds - , St James' University Hospital
- • Oxford - Churchill Hospital
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
ATTR-01 is the experimental drug being studied in the ATTEST clinical trial. The drug is made from a common cold virus that has been changed to only infect and multiply in cancer cells. This virus delivers an immune therapy drug into the cancer that is intended to promote a participant's own immune system to attack the cancer. The first part of this trial (sub-protocol A) is a phase 1 trial including dose escalation and expansion at one or more doses. It is the first time that ATTR-01 will be given to humans. If an optimal dose is identified, additional sub-protocols will be added by to further elicit whether ATTR-01 may successfully treat cancer. Expanded access is not available.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
Biomarkers mentioned
Treatment history
Treatments you must have had:
- ✓ washout
What the study is looking for
- ✓Received and failed/intolerant of the usual treatment (SoC) therapy where eligible (not including before surgery).
- ✓Tumour lesion (not previously irradiated), suitable for safe pre- and post-treatment biopsies.
- ✓cancer that can be measured on scans by Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1.
- ✓activity scale (ECOG) Performance Status (PS) of 0 or 1.
- ✓Minimum life expectancy anticipated to be greater than three months
Who cannot take part
- ✗Significant degree of fibrotic disease, including autoimmune diseases (e.g. systemic lupus, rheumatoid arthritis) or...
- ✗Known prior history of intolerance to anti-programmed cell death protein 1 (PD-1) and/or anti-PD-L1 treatment that helps your immune system fight cancer...
- ✗Has any of the comorbid conditions listed in the detailed protocol exclusion criteria.
See the full criteria
Where Is This Study? (4 UK sites)
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
Velindre Cancer Centre
Cardiff, United Kingdom
, St James' University Hospital
Leeds, United Kingdom
Churchill Hospital
Oxford, United Kingdom
How to Get in Touch
Hardev Pandha, Professor
Sponsor contactCONTACT